In the past week, RGEN stock has gone down by -14.53%, with a monthly decline of -28.78% and a quarterly plunge of -20.29%. The volatility ratio for the week is 4.96%, and the volatility levels for the last 30 days are 5.41% for Repligen Corp The simple moving average for the past 20 days is -17.47% for RGEN’s stock, with a -21.58% simple moving average for the past 200 days.
Is It Worth Investing in Repligen Corp (NASDAQ: RGEN) Right Now?
RGEN has 36-month beta value of 1.22. Analysts have mixed views on the stock, with 9 analysts rating it as a “buy,” 4 as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for RGEN is 53.02M, and currently, short sellers hold a 7.16% ratio of that float. The average trading volume of RGEN on April 04, 2025 was 674.91K shares.
RGEN) stock’s latest price update
The stock of Repligen Corp (NASDAQ: RGEN) has decreased by -6.30 when compared to last closing price of 121.70.Despite this, the company has seen a loss of -14.53% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-20 that I reiterate a ‘buy’ rating for Repligen with a one-year price target of $175 per share, driven by strong bioprocessing market recovery. Repligen reported 3% organic revenue growth and 13% growth in non-COVID business, with record-high order intakes since Q2 FY22. The acquisition of 908 Devices’ bioprocessing analytics portfolio enhances Repligen’s process analytical technology, adding significant value to its offerings.
Analysts’ Opinion of RGEN
Many brokerage firms have already submitted their reports for RGEN stocks, with Evercore ISI repeating the rating for RGEN by listing it as a “In-line.” The predicted price for RGEN in the upcoming period, according to Evercore ISI is $155 based on the research report published on March 18, 2025 of the current year 2025.
TD Cowen, on the other hand, stated in their research note that they expect to see RGEN reach a price target of $200. The rating they have provided for RGEN stocks is “Buy” according to the report published on February 10th, 2025.
Canaccord Genuity gave a rating of “Hold” to RGEN, setting the target price at $165 in the report published on December 17th of the previous year.
RGEN Trading at -24.21% from the 50-Day Moving Average
After a stumble in the market that brought RGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.52% of loss for the given period.
Volatility was left at 5.41%, however, over the last 30 days, the volatility rate increased by 4.96%, as shares sank -29.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.71% lower at present.
During the last 5 trading sessions, RGEN fell by -17.84%, which changed the moving average for the period of 200-days by -11.85% in comparison to the 20-day moving average, which settled at $137.95. In addition, Repligen Corp saw -20.78% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RGEN starting from Hunt Anthony, who sale 26,756 shares at the price of $152.51 back on Mar 17 ’25. After this action, Hunt Anthony now owns 136,301 shares of Repligen Corp, valued at $4,080,663 using the latest closing price.
Pax Margaret, the Director of Repligen Corp, purchase 250 shares at $150.69 during a trade that took place back on Mar 17 ’25, which means that Pax Margaret is holding 1,043 shares at $37,672 based on the most recent closing price.
Stock Fundamentals for RGEN
Current profitability levels for the company are sitting at:
- -0.07 for the present operating margin
- 0.49 for the gross margin
The net margin for Repligen Corp stands at -0.05. The total capital return value is set at -0.02. Equity return is now at value -1.30, with -0.90 for asset returns.
Based on Repligen Corp (RGEN), the company’s capital structure generated 0.25 points at debt to capital in total, while cash flow to debt ratio is standing at 0.26. The debt to equity ratio resting at 0.34. The interest coverage ratio of the stock is -2.57.
Currently, EBITDA for the company is 113.34 million with net debt to EBITDA at -0.7. When we switch over and look at the enterprise to sales, we see a ratio of 10.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.41.
Conclusion
To put it simply, Repligen Corp (RGEN) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
